ECM boosters are the fastest-growing booster category in Korean aesthetic medicine right now. Where earlier boosters signaled the skin to produce collagen, ECM boosters place structural material directly into the dermis — extracellular matrix taken from donated human dermal tissue with the cells removed. At DayBeau Gangnam we work with two of them: Re2O and CellREDM.
Over the past decade or so, skin boosters have changed direction three times.
First, they filled. Hyaluronic acid placed into the dermis to restore water content. The effect is clear and it arrives quickly, but once what was placed is absorbed, the skin returns to where it started.
Then they prompted. Treatments like Rejuran, using polynucleotides from salmon, set up the conditions for the skin to build its own collagen. Slower to show, but what changes is the skin itself. Synthetic polymers that induce collagen through the body's response to them belong to this branch as well.
And now they place directly. Rather than asking the skin to build, bring what is already built. These are ECM boosters.
A note on numbering: the industry tends to assign generation numbers to this sequence — third, fourth, fifth. Since the numbers are assigned differently depending on who is introducing the product, we describe the categories by what they actually do instead.
The extracellular matrix is the whole mesh that makes up the dermis.
Collagen provides the framework. Elastin gives it the capacity to return. Glycosaminoglycans hold water. Woven together, these form the structure within which skin cells settle and do their work. The ECM is both the material the skin is made of and the environment its cells live in.
Understanding aging purely as declining collagen sees only half the picture. What actually happens is that the whole mesh grows loose. New collagen matters less when the structure it settles into has slackened.
This is where the idea behind ECM boosters comes from: restore the environment, not just the material.
The material ECM boosters use is called hADM — human acellular dermal matrix.
It begins as donated human skin tissue. Cells, genetic material and the elements capable of provoking an immune response are removed, leaving only the ECM structure. Refined into fine particles, it is then placed into the dermis.
The material itself is not new. In Korea, acellular dermal matrix has long been used in reconstructive care for burn patients, and it is handled under the Human Tissue Safety and Management Act. What is new is its use in aesthetic treatment.
That human origin means two things. It places these treatments under a different regulatory framework from conventional fillers and synthetic boosters. And because what is placed is the same kind of material the skin is already made of, the treatment does not rely on the body recognizing something foreign — which is why the category is generally understood to carry a lower likelihood of foreign-body reaction.
Re2O arrived in 2024, developed on the back of Korea's human tissue regeneration expertise. Its weight falls on the density and substance of the dermis.
CellREDM followed in 2025, from the company that established Korea's first tissue bank. According to the manufacturer, its particles are processed especially fine so that the material disperses evenly across the dermis.
The two share a principle but differ in developer and in processing. Which one suits you depends on the thickness of your skin, the area being treated, and what you have had done before — decided in consultation.
A newer category does not replace what came before it. It approaches differently.
Rejuran and treatments like it address the skin's capacity to recover, a direction that doesn't overlap, which is why the two are often designed together — one raising the density of the foundation, the other supporting the skin's own repair above it. We compare the two directly in our piece on choosing between them.
Lifting energies send their signal to the deep layers that support the face, while ECM boosters work on the density of the dermis above. Different layers, so no interference.
ECM boosters are genuinely the treatment of the moment. That is not, on its own, a reason to have one.
What a doctor assesses is whether the dermis has actually thinned, or whether hydration at the surface or the skin's capacity to recover is the more immediate concern. Adding density to skin whose problem was never density gives back less than the time it takes.
At DayBeau Gangnam, we assess the condition of your skin before settling on a category and a product. Because responses and duration differ from person to person, the decision follows the diagnosis.
The question an ECM booster poses is not what more to put into the skin. It is how to give back the structure the skin has lost.
Neither is positioned above the other. They share the same principle and differ in developer and in how the material is processed. The choice follows your skin's thickness, the area being treated, and your treatment history — which is what the consultation is for.
Yes. The two work in different directions — one supports the skin's own repair, the other supplies structural material — so they are often designed together rather than chosen between. Your doctor will advise on sequencing.
The tissue is donated and processed so that cells, genetic material and immune-reactive elements are removed. In Korea it is handled under the Human Tissue Safety and Management Act. Your consultant will walk you through the material and its documentation before you decide.
If this sounds like your concern, these are the treatment pages to explore:
Written by the DayBeau Gangnam Medical Team · Medically reviewed by the DayBeau Gangnam Medical Team
Our consultants read your skin first, then the category.
Book a consultation→
